YMRC
AXSM icon

Yorktown Management & Research Company’s Axsome Therapeutics AXSM Stock Holding History

Yorktown Management & Research Company’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
4,850
+1,250
+35% +$271K 0.73% 20
2026
Q1 		$608K Buy
3,600
+1,900
+112% +$328K 0.51% 60
2025
Q4 		$310K Buy
+1,700
New +$237K 0.25% 169

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Yorktown Management & Research Company's AXSM Position: Q2 2026 in Review

Yorktown Management & Research Company increased its Axsome Therapeutics (AXSM) stake by 35% in Q2 2026, buying an estimated $271K and bringing the position to 4,850 shares worth $1.19M. The position accounts for 0.73% of the portfolio, ranked #20.

Yorktown Management & Research Company first reported a position in AXSM in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Yorktown Management & Research Company held 4,850 shares of Axsome Therapeutics worth $1.19M as of Q2 2026.
  • Yorktown Management & Research Company bought 1,250 Axsome Therapeutics shares in Q2 2026, an estimated $271K.
  • Axsome Therapeutics made up 0.73% of Yorktown Management & Research Company's portfolio in Q2 2026, its #20 holding.
  • Yorktown Management & Research Company first reported a position in Axsome Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.